. 2021 Oct 9;9(10):1421. doi: 10.3390/biomedicines9101421

Table 2.

Monoclonal antibodies shown to protect mice in pneumonic plague models (intranasal instillation or exposure to aerosolized bacteria).

Antigen ^a	mAb Description	Antibody/Therapeutic Administration			Y. pestis Challenge Strain ^f	Challenge Dose (LD₅₀)	Ref.
Antigen ^a	mAb Description	Route	Concentration	Schedule	Y. pestis Challenge Strain ^f	Challenge Dose (LD₅₀)	Ref.
LcrV	mouse IgG1	IP	35 µg	4 h pre–96 h post	GB	88	156
LcrV ^b	mouse IgG1	IP	200 or 400 µg	1 h pre	CO92 ^g	15–20	194
LcrV ^c	mouse IgG2b	IP, IV	100–500 µg, 10¹¹ pu ^e	94 h pre–24 h post	CO92 ^g	363–9080	195
F1 ^d	mouse IgG1	IP	125–500 µg	6 h or 24 h pre	CO92	29–74	199
F1 + LcrV	mouse IgG1	IT	77.5 µg (each)	2 h post	GB	27	200

a, unless otherwise noted mAbs tested in BALB/c female mice; b, tested in C57BL/6 female mice; c, tested in BALB/c female and C57BL/6 male mice; d, tested in Swiss Webster female mice; e, antibodies delivered as hybridoma supernatant or via adenovirus vector; f, unless otherwise noted aerosolized bacteria were delivered; g, intranasal instillation was used for challenge